Venous Thromboembolism Devices Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Venous Thromboembolism Devices Market by type of Device( Compression Stockings, Gradual or medical compression stockings, Anti-embolism stockings, Nonmedical support hosiery, Intermitted pneumatic compression devices, Inferior vena cava filters, Retrievable IVC filters, Permanent IVC Filters), By Disease Type ( Deep vein thrombosis, Pulmonary embolism) end-user (Hospitals, Diagnostic centres, Ambulatory surgical centres) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Venous Thromboembolism Devices Market Size was valued at USD 956 million in 2021, growing at a CAGR of 8.6% during the forecast period 2022-28. The global market provides a detailed overview and which can be segmented by type of device, disease type, end user, and region. By type of device, the venous thromboembolism devices market has been segmented into compression stockings, gradual or medical compression stockings, anti-embolism stockings, nonmedical support hosiery, intermitted pneumatic compression devices, inferior vena cava filters, retrievable IVC filters, permanent IVC filters. By disease type, the venous thromboembolism devices market has been segmented into deep vein thrombosis and pulmonary embolism. By disease type, the pulmonary embolism segment held the largest revenue share of the venous thromboembolism devices market in past years and is expected to have the fastest growth rate over the forecasted period due to its increasing diseases rate globally. Based on the end user, the segment has been segregated into hospitals, diagnostic centers, and ambulatory surgical centers. The hospital segment is expected to lead the end-user segments owing to the increasing patient population which in turn increases the hospitalization rate worldwide.

Key Development:

In June 2021, Janssen Pharmaceuticals, Inc, a Belgium-based pharmaceutical company, announced receiving Food and Drug Administration (FDA) approval for its new product XARELTO® (rivaroxaban) for the treatment of two indications – deep venous thrombosis and pulmonary embolism. This will assist the company to strengthen its footprint in the market.

Venous Thromboembolism Devices Market

MARKET SUMMARY
-
8.6% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 8.6%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Venous Thromboembolism Devices Market

  • Venous Thromboembolism Devices Market gives historical, current, and future market sizes (US$ Mn) of product type and distribution channel and geographic regions.
  • Key stakeholders of the market report include suppliers, manufacturers, marketers, policy makers engaged in manufacturing and supply of Infant nutrition
Key Players
  • Baxter International Inc.
  • Lidco Group Plc
  • All Pro Corporation
  • Abbott Laboratories
  • Accellent, Inc
Venous Thromboembolism Devices Market Dynamics

Increasing prevalence of pulmonary embolism disease is one of the leading factors driving the growth in the market. For instance, according to the Centers for Disease Control and Prevention, about 900,000 people in the U.S. are affected by pulmonary embolism, causing around 60,000 to 100,000 deaths every year. As several patients are at high risk of developing more serious venous thromboembolism, therapeutics such as retrievable vena cava filters are increasingly being used to stop the progression of malignant pulmonary embolism. This is further expected to enhance the sales of venous thromboembolism treatments in the market.


North-America Got Significant Share

Venous Thromboembolism Devices Market

By region, the North America market is expected to witness the highest market share during the forecast period owing to favorable reimbursement policies favoring the demand for thromboembolic therapy in the U.S. Additionally, the region also offers high incentives to doctors and physicians to use filters for prophylactic treatments. These factors are expected to accelerate the sales of venous thromboembolism treatments in the U.S.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

KEY FEATURES OF THE REPORT

  • The report provides granular level information about the market size, regional market share, historic market (2016 to 2021) and forecast (2022 to 2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Venous Thromboembolism Devices Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The venous thromboembolism devices market is projected to expand at a CAGR of 8.6% during the forecast period

 

Fukuda Denshi Co., Ltd (Japan), Baxter International Inc, Lidco Group Plc, All Pro Corporation, Abbott Laboratories

North America is the fastest-growing region for venous thromboembolism devices market

In terms of indication, the deep venous thrombosis segment is expected to account for a significant share of the total venous thromboembolism treatment sales market in 2022.


Report

Table Of Content


Report

Company Profile

  • Fukuda Denshi Co., Ltd (Japan)
  • Baxter International Inc. (U.S)
  • Lidco Group Plc. (U.K)
  • All Pro Corporation (China)
  • Abbott Laboratories (U.S)
  • Accellent, Inc.(U.S)
  • Cardiva Medical, Inc.(U.S)
  • Biosensors International Group, Ltd.(Singapore)
  • 3M Healthcare (U.S)

Description

Venous Thromboembolism Devices Market Size was valued at USD 956 million in 2021, growing at a CAGR of 8.6% during the forecast period 2022-28. The global market provides a detailed overview and which can be segmented by type of device, disease type, end user, and region. By type of device, the venous thromboembolism devices market has been segmented into compression stockings, gradual or medical compression stockings, anti-embolism stockings, nonmedical support hosiery, intermitted pneumatic compression devices, inferior vena cava filters, retrievable IVC filters, permanent IVC filters. By disease type, the venous thromboembolism devices market has been segmented into deep vein thrombosis and pulmonary embolism. By disease type, the pulmonary embolism segment held the largest revenue share of the venous thromboembolism devices market in past years and is expected to have the fastest growth rate over the forecasted period due to its increasing diseases rate globally. Based on the end user, the segment has been segregated into hospitals, diagnostic centers, and ambulatory surgical centers. The hospital segment is expected to lead the end-user segments owing to the increasing patient population which in turn increases the hospitalization rate worldwide.

Key Development:

In June 2021, Janssen Pharmaceuticals, Inc, a Belgium-based pharmaceutical company, announced receiving Food and Drug Administration (FDA) approval for its new product XARELTO® (rivaroxaban) for the treatment of two indications – deep venous thrombosis and pulmonary embolism. This will assist the company to strengthen its footprint in the market.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX